Suppr超能文献

在乳腺肿瘤模型中,环磷酰胺诱导胸苷磷酸化酶表达并增强卡培他滨或5'-脱氧-5-氟尿苷的疗效。

Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.

作者信息

Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y

机构信息

Cytostatics Group, Nippon Roche Research Center, Kamakura, Kanagawa, Japan.

出版信息

Int J Cancer. 1999 Sep 24;83(1):127-34. doi: 10.1002/(sici)1097-0215(19990924)83:1<127::aid-ijc22>3.0.co;2-6.

Abstract

Thymidine phosphorylase (dThdPase) is an essential enzyme for the activation of the oral cytostatic drugs capecitabine (N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine, Xeloda(trade mark)) and its intermediate metabolite doxifluridine [5'-deoxy-5-fluorouridine (5'-dFUrd, Furtulon((R)))] to 5-fluorouracil (5-FUra) in tumors. In a previous study, we found that several cytostatics were able to up-regulate tumor levels of dThdPase in a human colon cancer xenograft model. In the present study, we confirmed that the administration of cytostatics used for breast cancer treatment, such as taxanes and cyclophosphamide (CPA), up-regulated the tumor level of dThdPase in mammary tumor models as well. Because the dThdPase up-regulation was observed even when CPA was given orally, we investigated further the usefulness of combination therapy with the 2 oral drugs, 5'-dFUrd/capecitabine and CPA in mammary tumor models. Daily oral administration of CPA up-regulated human dThdPase levels in the tumor tissue of mice bearing a human mammary tumor xenograft, MX-1, whereas in the small intestine and liver, it did not affect levels of pyrimidine nucleoside phosphorylases (PyNPase) including dThdPase and uridine phosphorylase. The preferential up-regulation of PyNPase activity in the tumor by CPA administration was also confirmed in mice bearing a syngeneic murine mammary adenocarcinoma, A755. In both models, combination therapy of 5'-dFUrd/capecitabine with CPA showed synergistic antitumor activity, without significant potentiation of toxicity. In contrast, treatment with CPA and either 5-FUra or UFT (a mixture of tegafur and uracil) in combination showed only additive activity. Our results suggest that CPA and capecitabine/5'-dFUrd, both available for oral administration, would be good partners, and that clinical trials with this drug combination against breast cancer are warranted.

摘要

胸苷磷酸化酶(dThdPase)是激活口服细胞抑制药物卡培他滨(N(4)-戊氧基羰基-5'-脱氧-5-氟胞苷,希罗达(商标名))及其中间代谢产物多西氟尿苷[5'-脱氧-5-氟尿苷(5'-dFUrd,呋氟脲嘧啶(注册商标))]使其在肿瘤中转化为5-氟尿嘧啶(5-FUra)的关键酶。在之前的一项研究中,我们发现几种细胞抑制药物能够在人结肠癌异种移植模型中上调肿瘤组织中dThdPase的水平。在本研究中,我们证实用于乳腺癌治疗的细胞抑制药物,如紫杉烷类和环磷酰胺(CPA),在乳腺肿瘤模型中也能上调肿瘤组织中dThdPase的水平。由于即使口服CPA也能观察到dThdPase的上调,我们进一步研究了在乳腺肿瘤模型中2种口服药物5'-dFUrd/卡培他滨与CPA联合治疗的有效性。每日口服CPA可上调携带人乳腺肿瘤异种移植瘤MX-1的小鼠肿瘤组织中人dThdPase的水平,而在小肠和肝脏中,它不影响包括dThdPase和尿苷磷酸化酶在内的嘧啶核苷磷酸化酶(PyNPase)的水平。在携带同基因小鼠乳腺腺癌A755的小鼠中也证实了CPA给药后肿瘤中PyNPase活性的优先上调。在这两种模型中,5'-dFUrd/卡培他滨与CPA联合治疗均显示出协同抗肿瘤活性,且无明显毒性增强。相比之下,CPA与5-FUra或优福定(替加氟和尿嘧啶的混合物)联合治疗仅显示出相加活性。我们的结果表明,均可口服的CPA和卡培他滨/5'-dFUrd将是很好的组合,有必要对这种药物组合进行抗乳腺癌的临床试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验